ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VAL Valirx Plc

4.05
-0.20 (-4.71%)
04 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.20 -4.71% 4.05 111,491 16:26:53
Bid Price Offer Price High Price Low Price Open Price
4.00 4.10 4.25 4.05 4.25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories -2.37M -0.0262 -1.55 3.65M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:15:07 O 20,000 4.20 GBX

Valirx (VAL) Latest News (6)

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date Time Title Posts
04/3/202423:16VALIRX - A Significantly Undervalued Pharma9,803
01/3/202418:24RAINMAKER'S VALUE THREAD8,548
21/2/202419:15*** Value ONLY ***43
08/8/202214:25Valirx May 1st 2020 a New era begins2,131
20/10/202118:02BITCOIN TRADING1

Add a New Thread

Valirx (VAL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-04 16:15:084.2020,000840.00O
2024-03-04 16:10:484.0560,0002,429.34O
2024-03-04 14:25:454.2015,500650.23O
2024-03-04 12:55:234.202,710113.82O
2024-03-04 12:28:064.272349.98O

Valirx (VAL) Top Chat Posts

Top Posts
Posted at 04/3/2024 08:20 by Valirx Daily Update
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 4.25p.
Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £3,652,053.
Valirx has a price to earnings ratio (PE ratio) of -1.55.
This morning VAL shares opened at 4.25p
Posted at 01/2/2024 02:23 by porky9
@Wulber
This is why the BOD get away with it
17 raises, three 125:1 consolidations, raise, spend, raise ,spend, consolidate, no revenue in 15 years, shareholders completely and utterly shafted and yet there will always be some that will come back for yet more of the same.
I find it absolutely incredible.
They will simply give each other pay rises and nice bonuses and squander the bloody lot and be back for raise number 18 in September and that will likely get supported by those in the know pumping it and shorting it ahead of its placing.
Nothing will change here until the BOD is replaced

As for quoting Buffet, he also follows three golden rules when deciding which companies to invest in:-
1. They must earn good returns on the net tangible capital required in their operation
2. They must be run by honest and able managers
3. The stock must be available at a sensible price

VAL fails on all three counts. 1. they have delivered FA returns, 2. I will let you make up your own mind but at best a demonstration of complete lack of any commercial acumen and 3. The market cap is only worth a quarter of what it is currently at best, about £2m if lucky and once proven 201 wont get executed the share price will rapidly drop to that level 1.5p to 2p by the end of June AGM watch this space.

The share price is only at this ridiculously high price due to the pump and hype campaign, I just feel sorry for those trapped holding this that were suckered in by it all
Posted at 31/1/2024 10:23 by jasonpugh
Euda in trouble

For euda to remain in the nasdaq market it must maintain a Mcap of $35mill for 30 consecutive days. After yesterday’s fall its share price is $1.33 per share. What do this equate to in Mcap?
According to invest.com the following.
Mcap =no of share x share price.
Euda=. 24.628mill shares x $1.33= $32.755 mcap. Oh dear 🤦‍a94;️
So what is the minimum requirement for share price to reach for 30 consecutive days?
A. $35mill divided by number of shares(24.628) = $1.42 per share.
Oh dear. 9p deficit lol 🤦‍a94;️. No way is Theormrx merging with this tin pot company. Valirx is doomed 🤦‍a94;️. Abandon ship 🚢
Posted at 29/1/2024 10:52 by jasonpugh
Newsflash. Adam Hargreaves has resigned from Valirx scientific advisory board.

Q. Why isn’t the biggest shareholder by far calling for an EGM?
A. Wanting val to go into administration so his company and Suzy company can steal the assets. Remember Val got them at over 40 times cheaper.
Q. Why did suzy buy only £4K worth of shares at the placing?
A. No need to answer this one 🤦‍a94;️
Q. In the video on q and a last year Stella Panu was asked why she had not purchased Val shares and her answer was valirx was uninvestable. Why did she say this?
A. Because she was shorting it. 👍
lol 👇. DYOR
Posted at 25/1/2024 20:43 by jasonpugh
Neotheone. Love you bro 👊
Miss the jedi talk.

On a serious note you have very valid arguments. Suzy and dr Kevin are enept to an extent of being unbelievable. I agree to some extent on porky comments. However it’s not invested …🤷 7995;. So the only explanation is it’s on the slater payroll. PAYE of course as this zygote couldn’t do its own tax returns (only joking).

But seriously I have been in valirx for 6 years. Traded of course. But one strikingly obvious observation that I have noticed is the gradual deliberate decimation of the share price. You see. Our board have an accumulated asset value especially with imergan £150k for £6mill value. They also have adam at his own company. Suzy at her own company. It’s all set up for admin to steal the whole assets including clx001 on collapse. That is why suzy has gone radio silence.
Such a sad case of potential cancer mismanagement. It may get the 201 over the line…but think??? Why do a placing so close to euda theormrx merger deadline? Answer. Suzy has been tipped off. She knows it will drag. Hence the enormous £4K investment. Lol
Posted at 18/1/2024 12:54 by porky9
Also, if any of the perma bulls around would like to challenge me on my valuation comments I would welcome that if I have overlooked something? I seriously don’t see this business valued at anything remotely near the £7.35m the current value, the 5.5p Share Price – you are literally buying the “Emperor’;s New Clothes” as there is NOTHING worth investing into, show me where there is any value in the near term?

Let me break it down: -

1. Inaphaea labs – This is now what this business is all about. Suzy’s pet project. So, you have a start up lab business eating cash led by directors that have NEVER built or scaled a business from ground up. The model is highly labour intensive. They have three scientists. Imogen at its height had over 36 staff and still couldn’t make it viable. Now they want to waste £600k of your cash expanding the Imogen Biobank and £200k on developing the lab brand – that’s half the cash raised in this lab!!! Yet they can’t make what they have pay? I will be interested to see what the three months contract they won was worth when they issue to results to the end of December, I suspect it was a token fee.

As I see it, its going to take a heck of a lot of time and more cash to establish this lab and investors did not sign up for that, the BOD took them down this path. Most UK labs are loss making, the best in the market can only deliver up to a 20% return due to its a highly labour-intensive model. Valirx would probably need something like north of £10m revenue to generate gross profits to cover existing overheads and that’s assuming no increase in head count.

2. Stingray – So another £100k of cost and won’t know until after November 24 end of current evaluation phase. So, lets call that WIP for a year plus. No immediate cash return if ever.

Then we move onto the main assets the Clinical Stage Assets: -

3. 201 – well IMO forget it, now over 14 years old and still awaiting on THX. They won’t execute the LOI but those still with faith in Suzy will need to allow it to run its course. By end of June AGM, the penny should finally drop. It’s a total dead duck. So zero revenue from here.

4. 401 – why that was handed to another business heaven knows, clearly VALs lab lacked the experience to take it inhouse but another start up with effectively an LOI that won’t get executed. So, no value here either, certainly not in the next year if ever.

Then we move to pre-clinical assets: -

5. CLX – well they are spending 200k more on it and it needs another year of work plus so you will be waiting a good while on that one. It has potential IMO I like it but years off anything to deliver a financial return.

6. VAL 301 – again some of the 200k being spent on that. Its so outdated now that it will need all its IP patents revising and updating so that one is years off, if ever IMO with more cost on it but with it being 14 years old like 201 is it worth it now? Who’s knows but certainly no financial return anytime soon.

7. BC201 – no idea, was going to do something with covid a while back, missed opportunity anyhow as I see it. No follow up and badly managed like the other assets IMO.

8. AND finally we have £200k earmarked for new evaluations. Well previously they ignored new evaluations to focus on the start up lab and anything found now is at least a year away from being taken to the next stages. So no value here yet either.

So, as you can see there is next to nothing here worth investing in. How they got the recent placing away at this eye watering valuation is beyond me. The entire board are culpable for the dire decisions made here and frankly they all need replacing IMO before this becomes even remotely investable.

The share price will continue to drift until the changes are made. Come September they will be looking to raise again. 17 raises, three 125:1 consolidations and ZERO revenue excepting that 3 month lab contract – how have they got away with this?

Unfortunately, i believe we are stuck in this limbo until the AGM when BOD positions come up for election - hopefully the change will then come. Until then IMO AVOID
Posted at 04/1/2024 02:36 by porky9
I could be wrong but i highly suspect that Adam sold down from 14p hype bubble in order to support the placing at 6p giving the company more cash to squander whilst trying to maintain this ridiculously bloated over priced market cap. We will know for certain once the declared positions are confirmed.

No way on this planet is this business worth £ 8.4m fully diluted 140m shares at 6p should all resolutions get passed today. No way.

They can try and pump both 201 and 401 as deals with LOI's in progress but both are worth jack sh1t as neither will be executed imo. Further, labs will take years and buckets of further cash to establish. Its so labour intensive and a real cash drain. This really is buying the Emperors New Clothes, there is FA here now left of any value.

Punters are seriously deluded if they think EUDA with THX are going to raise north of £20m to cover phased trials for a 14 year old 201 candidate AND give VAL a chunk of cash on the table. Forget it.

The mcap was £2.25m back in April 21 restructure, the outlook was better then than it is now. Cash burn is way out of control again and all that will happen now is they will spend the lot and be back for more in September and the cycle will repeat. But SH have helped create this situation by supporting this placing at this ridiculous false level value.

A number in this placing are expecting to manipulate a pump, sucker some newbies in to get out on a spike with a profit. Not going to work. Sorry but IMO the share price is going to drift back down to the £2m mcap at best due to the placing price being too high. Hence why Suzy would only risk £4k of her own cash despite earning £160k plus benefits. Some here really need to wake up.

Once the nonsense with 201 is fully exposed you can totally write the share price off, the share price is only holding up at this silly level whilst hopeium remains that THX are going to complete on 201 - They wont IMO.

The ONLY thing that can change this situation is a total board clear out of the dead wood and its looking like its going to be the end of June AGM before you get that chance again and even then it wouldn't surprise me if Adam votes to keep them all in situ again - talk about doing the same thing and expecting a different result - total madness.

Sorry but the stock remains totally uninvestable
Posted at 03/1/2024 08:47 by neotheone
Very likely the TRX merger is DOA.If this is confirmed then its game over for the Val share price.
Posted at 02/1/2024 06:59 by neotheone
TheBasherToday 00:44Posts: 653Price: 5.90Aka THE YEAR OF THE LEPER...I've been in VAL for many years and still hold some shares to show it's catastrophic loss in my portfolio - it serves as a clear and daily reminder to me not to repeat mistakes of the past.On 16th Dec, the share price was 14p, and there were keyboard warriors claiming significant funds were coming in and that 20p, 30p, 40p and 50p or more was extremely likely. The share price is now at 5.9p. Says it all really and potential new investors should take note.Where are these rampers and keyboard warriors now? Soon shut their pie holes didnt they.
Posted at 14/12/2023 06:17 by neotheone
PatientInvestor813 Dec 2023 21:57Posts: 984Price: 7.75I'm not too concerned about the recent placing. It's a small placement that will likely be absorbed quickly.WCB, do you remember the placing at 10p and the subsequent Kings update, which pushed the share price to 21p in just a few days? Now, with Kings, Val 201, Val 401, and Val 301 in the picture, and potential addition of Adam to the BOD, I am optimistic about the future and foresee the share price reaching the 20s or even 30's by January!Enjoy your evening.I think the constant ramping of patient and pm2022 and their fairytale view of this investment and their sheer ignorance to see and admit they are dead wrong on this one and their blind optimism even after they have been proven wrong yet again after months of ramping proves beyond a doubt that they should not be paid any attention.
Posted at 08/12/2023 12:22 by jayj4u
Great post Ron!


Kings is the big fat elephant in the room no one talks about. Everyone is focused on Porky and Val 201 deal.

I think once Val 201 gets done then all eyes will be on Kings and share price will rocket.

Suzy would have PROVEN that she can deliever, not once but twice. Val 401 & Val 201.

Kings deal could blow both Val 201 and Val 401.
Valirx share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com